Land: Europäische Union
Sprache: Englisch
Quelle: EMA (European Medicines Agency)
belatacept
Bristol-Myers Squibb Pharma EEIG
L04AA28
belatacept
Immunosuppressants
Graft Rejection; Kidney Transplantation
Nulojix, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.
Revision: 20
Authorised
2011-06-17
34 B. PACKAGE LEAFLET 35 PACKAGE LEAFLET: INFORMATION FOR THE USER NULOJIX 250 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION BELATACEPT READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What NULOJIX is and what it is used for 2. What you need to know before you use NULOJIX 3. How to use NULOJIX 4. Possible side effects 5. How to store NULOJIX 6. Contents of the pack and other information 1. WHAT NULOJIX IS AND WHAT IT IS USED FOR NULOJIX contains the active substance belatacept which belongs to a group of medicines called immunosuppressants. These are medicines that reduce the activity of the immune system, the body's natural defences. NULOJIX is used in adults to prevent the immune system from attacking your transplanted kidney and causing transplant rejection. It is used with other immunosuppressive medicines, including mycophenolic acid and corticosteroids. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE NULOJIX DO NOT USE NULOJIX IF YOU ARE ALLERGIC to belatacept or any of the other ingredients of the medicine (listed in section 6). Allergic reactions related to belatacept use have been reported in the clinical studies. IF YOU HAVE NOT BEEN EXPOSED TO THE EPSTEIN-BARR VIRUS (EBV) or are uncertain of previous exposure, you must not be treated with NULOJIX. EBV is the virus that causes glandular fever. If you have not been exposed to it, you are at a higher risk of getting a type of cancer called post-transplant lymphoproliferative disorder (PTLD). If you are not sure if you have been infected with the virus before, ask your doctor. WARNINGS AND PRECAUTIONS Post-transplant lymphoproliferative disorder Treatment with NULOJIX increases th Lesen Sie das vollständige Dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT NULOJIX 250 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 250 mg of belatacept. After reconstitution, each ml of concentrate contains 25 mg belatacept. Belatacept is a fusion protein produced in Chinese hamster ovary cells by recombinant DNA technology. Excipient with known effect Each vial contains 0.55 mmol sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder for concentrate for solution for infusion (powder for concentrate). The powder is a white to off-white whole or fragmented cake. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS NULOJIX, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant (see section 5.1 for data on renal function). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be prescribed and supervised by specialist physicians experienced in the management of immunosuppressive therapy and of renal transplant patients. Belatacept has not been studied in patients with Panel Reactive Antibody (PRA) > 30% (who often require increased immunosuppression). Because of the risk of a high total burden of immunosuppression, belatacept should only be used in these patients after consideration of alternative therapy (see section 4.4). Posology _Initiation at the time of transplantation _ For transplant recipients receiving NULOJIX treatment from time of transplantation (“newly transplanted patients”), the addition of an interleukin-2 (IL-2) receptor antagonist is recommended. The recommended dose is based on patient body weight (kg). The dose and treatment frequency is given below. 3 TABLE 1: DOSE OF BELATACEPT FOR RENAL TRANSPLANT RECIPIENTS INITIAL PHASE DOSE Day of transplantation, prior to implantation (Day 1) 10 mg/kg Day 5, Day 14 and Day 28 10 mg/kg End of Week 8 and Week 12 after transplantation 10 mg/k Lesen Sie das vollständige Dokument